Wockhardt’s Breakthrough in Treating Drug-Resistant Meningitis

Wockhardt, a pharmaceutical company, has announced a significant breakthrough in treating drug-resistant meningitis with its investigational drug, Zaynich

Wockhardt’s shares have been locked at the upper circuit after this announcement, reflecting the market’s optimism about the drug’s potential. Zaynich has successfully treated over 35 critically ill patients in India and the US who were suffering from extremely drug-resistant infections. One notable case involved a 64-year-old patient with Type 2 diabetes and hypertension who showed significant improvement after being administered Zidebactam/Cefepime for three weeks.

The drug is currently undergoing multi-national Phase III clinical trials, expected to conclude within 2-3 months. Once the trials are complete, Wockhardt will seek necessary regulatory approvals and aims to launch the drug in the market by 2026. Habil Khorakiwala, Chairman of Wockhardt, highlighted the significant market potential for this molecule, with approximately 7 lakh patients in the US and 11 lakh patients in India. The cost of similar treatments in the US ranges from $8,000 to $10,000 per patient. Khorakiwala also mentioned that the company will explore out-licensing opportunities after completing the Phase III trials.